P752: TARGETING S100A9 IN THE MYELODYSPLASTIC INFLAMMATORY BONE MARROW MICROENVIRONMENT BY TASQUINIMOD IMPROVES THE SUPPORTIVE FUNCTION OF MESENCHYMAL STROMAL CELLS

• M. Wobus,
• E. Balaian,
• M. Lissner,
• R. Towers,
• U. Oelschlägel,
• R. Wehner,
• T. Chavakis,
• M. Törngren,
• H. Eriksson,
• E. Bondesson,
• U. Platzbecker,
• M. Bornhäuser,
• K. Sockel

Affiliations

M. Wobus

1 Department of Medicine 1, University Hospital TU Dresden, Dresden

E. Balaian

1 Department of Medicine 1, University Hospital TU Dresden, Dresden

M. Lissner

1 Department of Medicine 1, University Hospital TU Dresden, Dresden

R. Towers

1 Department of Medicine 1, University Hospital TU Dresden, Dresden

U. Oelschlägel

1 Department of Medicine 1, University Hospital TU Dresden, Dresden

R. Wehner

2 German Cancer Consortium (DKTK), Partner Site Dresden, and German Cancer Research Center (DKFZ), Heidelberg

T. Chavakis

4 Institute of Clinical Chemistry and Laboratory Medicine, University Hospital TU Dresden, Dresden, Germany

M. Törngren

5 Active Biotech AB, Lund, Sweden

H. Eriksson

5 Active Biotech AB, Lund, Sweden

E. Bondesson

5 Active Biotech AB, Lund, Sweden

U. Platzbecker

6 Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, Leipzig University Hospital, Leipzig, Germany

M. Bornhäuser

1 Department of Medicine 1, University Hospital TU Dresden, Dresden

K. Sockel

1 Department of Medicine 1, University Hospital TU Dresden, Dresden